Somatuline® Depot (lanreotide injectable)

This policy covers Somatuline Depot (lanreotide) only for the FDA‑approved long‑term treatment of acromegaly and does not support non‑oncology off‑label uses. Approval (up to 12 months) requires documented acromegaly with baseline IGF‑1 above the lab‑specific ULN, endocrinologist prescription/consult, evidence of inadequate response to or ineligibility for surgery/radiotherapy (or tumor‑related mass effects), and GH/IGF‑1 monitoring to guide dosing—typically starting 90 mg every 4 weeks with specified GH/IGF‑1‑based dose adjustments and 6‑week monitoring after extended‑interval changes.

"Lanreotide is indicated for the long-term treatment of acromegaly in individuals who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not a..."

Sign up to see full coverage criteria, indications, and limitations.